```
Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1645vlf
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Dec 17  The CA Lexicon available in the CAPLUS and CA files
 NEWS  3  Feb 06  Engineering Information Encompass files have new names
 NEWS  4  Feb 16  TOXLINE no longer being updated
 NEWS  5  Apr 23  Search Derwent WPINDEX by chemical structure
 NEWS  6  Apr 23  PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
 NEWS  7  May 07  DGENE Reload

 NEWS EXPRESS  May 23 CURRENT WINDOWS VERSION IS V6.0a,
               CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
               AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:10:44 ON 25 MAY 2001

=> file biosis, caba, caplus, embase, lifesci, medline, scisearch, uspatful, japio
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.30       0.30

FILE 'BIOSIS' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'CABA' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 11:11:44 ON 25 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.

FILE 'LIFESCI' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)
```

FILE 'MEDLINE' ENTERED AT 11:11:44 ON 25 MAY 2001

FILE 'SCISEARCH' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'USPATFULL' ENTERED AT 11:11:44 ON 25 MAY 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

=> s Chlamydia
L1 59198 CHLAMYDIA

=> s l1 and composition?
L2 1447 L1 AND COMPOSITION?

=> s l2 and treatment?
L3 925 L2 AND TREATMENT?

=> s l3 and Chlamydia trachomatis
L4 339 L3 AND CHLAMYDIA TRACHOMATIS

=> s l4 and vaccine?
L5 98 L4 AND VACCINE?

=> d l5 bib ab 1-98

L5 ANSWER 1 OF 98 CAPLUS COPYRIGHT 2001 ACS
AN 2000:402007 CAPLUS
DN 133:53686
TI Chlamydial antigens and genomic DNA sequences for **treatment** and diagnosis of chlamydial infection
IN Probst, Peter; Bhatia, Ajay; Skeiky, Yasir A. W.; Fling, Steven P.; Jen, Shyian; Stromberg, Erica Jean
PA Corixa Corporation, USA
SO PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000034483	A2	20000615	WO 1999-US29012	19991208
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6166177	A	20001226	US 1998-208277	19981208
PRAI	US 1998-208277	A	19981208		
	US 1999-288594	A	19990408		
	US 1999-410568	A	19991001		
	US 1999-426571	A	19991022		

AB Compds. and methods for the diagnosis and **treatment** of Chlamydial infection are disclosed. The compds. provided include polypeptides that contain at least one antigenic portion of a **Chlamydia** antigen and DNA sequences encoding such polypeptides. **Chlamydia** antigens were isolated by expression cloning of a

genomic DNA library of C. trachomatis LGV II, and shown to induce T cell proliferation and interferon-.beta. prodn. Immune responses of human PBMC and T cell lines are generated against the **Chlamydia** antigens. Pharmaceutical **compns.** and **vaccines** comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits contg. such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biol. samples.

L5 ANSWER 2 OF 98 CAPLUS COPYRIGHT 2001 ACS
AN 1999:819417 CAPLUS
DN 132:77610
TI Antigenic complex comprising immunostimulatory peptide, CD4, and chemokine receptor domain for HIV **treatment** and immune disorders
IN Wang, Chang Yi
PA United Biomedical Inc., USA
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9967294	A1	19991229	WO 1999-US14030	19990621
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6090388	A	20000718	US 1998-100409	19980620
	AU 9947048	A1	20000110	AU 1999-47048	19990621
	EP 1098910	A1	20010516	EP 1999-930523	19990621
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1998-100409	A2	19980620		
	WO 1999-US14030	W	19990621		

AB The invention provides peptides comprising a sequence homologous to a portion of the CDR-2 like domain of CD4, covalently linked to a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the prodn. in mammals of high titer polyclonal auto-antibodies, which are specific to CD4 surface complex. These auto-antibodies prevent binding of HIV viral particles to CD4+ cells. The peptides are useful in pharmaceutical **compns.**, to provide an immunotherapy for HIV infection and to protect against HIV infection.

RE.CNT 2
RE
(1) United Biomedical Inc; WO 9526365 A1 1995 CAPLUS
(2) Vita, C; Biopolymers 1998, V47, P93 CAPLUS

L5 ANSWER 3 OF 98 CAPLUS COPYRIGHT 2001 ACS
AN 1999:819416 CAPLUS
DN 132:77609
TI Peptide **composition** as immunogen for the **treatment** of allergy
IN Wang, Chang Yi; Walfield, Alan M.
PA United Biomedical Inc., USA
SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9967293	A1	19991229	WO 1999-US13959	19990621
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9945802	A1	20000110	AU 1999-45802	19990621
	BR 9911389	A	20010320	BR 1999-11389	19990621
	EP 1090039	A1	20010411	EP 1999-928818	19990621
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1998-100287	A2	19980620		
	WO 1999-US13959	W	19990621		

AB The invention provides peptides comprising a sequence homologous to a portion of the third const. domain of the epsilon heavy chain of IgE, covalently linked to either (1) a carrier protein, or (2) a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the prodn. in mammals of high titer polyclonal antibodies, which are specific to a target effector site on the epsilon heavy chain of IgE. The peptides are expected to be useful in pharmaceutical **compns**., to provide an immunotherapy for IgE-mediated allergic diseases.

RE.CNT 5
RE
(1) Burt, D; Eur J Immunol 1987, V17, P437 CAPLUS
(2) Burt, D; Molecular Immunology 1987, V24(4), P379 CAPLUS
(3) Genentech Inc; WO 9304173 A1 1993 CAPLUS
(4) Helm, B; Nature 1988, V331, P180 CAPLUS
(5) Vercelli, D; Letters to Nature 1989, V338, P649 CAPLUS

L5 ANSWER 4 OF 98 CAPLUS COPYRIGHT 2001 ACS
AN 1999:375673 CAPLUS
DN 131:14867
TI **Chlamydia trachomatis** genomic sequence and polypeptides and their fragments and uses for the diagnosis, prevention and **treatment** of infection
IN Griffais, Remy
PA Genset, Fr.
SO PCT Int. Appl., 292 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9928475	A2	19990610	WO 1998-IB1939	19981127
	WO 9928475	A3	19991118		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

	AU 9912545	A1	19990616	AU 1999-12545	19981127
	EP 1032676	A2	20000906	EP 1998-955832	19981127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9814912	A	20001003	BR 1998-14912	19981127
PRAI	FR 1997-15041	A	19971128		
	FR 1997-16034	A	19971217		
	US 1998-107077	P	19981104		
	WO 1998-IB1939	W	19981127		

AB The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of **Chlamydia trachomatis**, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metab., in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The complete genome sequence of C. trachomatis strain LSV2, as well as 1196 open reading frames and the deduced amino acid sequences of their protein products, are claimed in the patent but not provided in the document. The invention also relates to transcriptional gene products of the **Chlamydia trachomatis** genome, such as, for example, antisense and ribozyme mols., which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing **Chlamydia trachomatis** infection. The invention also relates to a method of selecting compds. capable of modulating bacterial infection and a method for the biosynthesis or biodegrdn. of mols. of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular **vaccine, compns.** for the prevention and/or **treatment** of bacterial, in particular **Chlamydia trachomatis**, infections.

L5 ANSWER 5 OF 98 CAPLUS COPYRIGHT 2001 ACS
AN 1999:244557 CAPLUS
DN 130:277672
TI **Chlamydia** high-molecular-weight protein and its gene sequence and and diagnostic and therapeutic uses
IN Jackson, James W.; Pace, John L.
PA Antex Biologics Inc., USA
SO PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9917741	A1	19990415	WO 1998-US20737	19981001
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9895988	A1	19990427	AU 1998-95988	19981001
	EP 1019028	A1	20000719	EP 1998-949723	19981001
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9813841	A	20001003	BR 1998-13841	19981001
	ZA 9809012	A	19990412	ZA 1998-9012	19981002
PRAI	US 1997-942596	A	19971002		
	WO 1998-US20737	W	19981001		

AB A high-mol.-wt. (HMW) protein of **Chlamydia**, the amino acid

sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. The gene encoding HMW protein was cloned and sequenced from C. trachomatis strains L2, B, and F. The in vitro neutralization model shows that protective antiserum against HMW protein inhibits chalmydial infections of various tissue culture cell lines. **Vaccine compns.** comprising the HMW protein are effective in a mouse model of salpingitis and fertility. Thus, disclosed are prophylactic and therapeutic **compns.**, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including **vaccines**.

RE.CNT 4
RE
(1) Caldwell; US 4427782 A 1984 CAPLUS
(2) Daniels; US 5725863 A 1998 CAPLUS
(3) Morrison; US 5071962 A 1991 CAPLUS
(4) Urnovitz; US 5516638 A 1996 CAPLUS

L5 ANSWER 6 OF 98 CAPLUS COPYRIGHT 2001 ACS
AN 1997:332018 CAPLUS
DN 126:304912
TI **Vaccines** and pharmaceutical **compositions** using membrane vesicles of microorganisms, and methods for preparing them
IN Kadurugamuwa, Jagath L.; Beveridge, Terry J.
PA University of Guelph, Can.
SO Can. Pat. Appl., 116 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2182637	AA	19970205	CA 1996-2182637	19960802
	WO 9705899	A2	19970220	WO 1996-CA526	19960802
	WO 9705899	A3	19970529		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
	AU 9666095	A1	19970305	AU 1996-66095	19960802
	AU 707131	B2	19990701		
	EP 841944	A2	19980520	EP 1996-925628	19960802
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, PT, IE, FI				
	BR 9609882	A	19990727	BR 1996-9882	19960802
PRAI	US 1995-1903		19950804		
	WO 1996-CA526		19960802		

AB The invention relates to novel **vaccines** and pharmaceutical **compns.** using membrane vesicles of microorganisms, methods for prepg. same, and their use in the prevention and **treatment** of infectious diseases. Demonstrated were membrane vesicles (MVs) prepd. and characterized Pseudomonas aeruginosa, integration of MVs of Pseudomonas aeruginosa or Shigella flexneri carrier strain (i.e. Escherichia coli or Salmonella typhi), predatory role of Pseudomonas aeruginosa-derived MVs on other bacteria (Streptococcus aureus, Escherichia coli) and use as drug delivery system for gentamicin into human intestinal epithelial cell line Henle 407, and construction of Salmonella typhi **vaccine** by fusion of Pseudomonas aeruginosa- or Shigella flexneri-derived MVs with S. typhi.

L5 ANSWER 7 OF 98 USPATFULL

AN 2001:74943 USPATFULL
TI DNA immunization against chlaymdia infection
IN Brunham, Robert C., Winnipeg, Canada
PA University of Manitoba, Winnipeg, Canada (non-U.S. corporation)
PI US 6235290 20010522
AI US 1997-893381 19970711 (8)
DT Utility
EXNAM Primary Examiner: Swartz, Rodney P.
LREP Sim & McBurney
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 995
AB Nucleic acid, including DNA, immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of **Chlamydia**, preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

L5 ANSWER 8 OF 98 USPATFULL
AN 2001:71101 USPATFULL
TI Strategically modified hepatitis B core proteins and their derivatives
IN Birkett, Ashley J., Solana Beach, CA, United States
PA Immune Complex Corporation, San Diego, CA, United States (U.S. corporation)
PI US 6231864 20010515
AI US 1999-248588 19990211 (9)
PRAI US 1998-74537 19980212 (60)
DT Utility
EXNAM Primary Examiner: Wortman, Donna C.
LREP Welsh & Katz, Ltd.
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1665
AB A strategically modified hepatitis B core protein is described, where an insert is provided, preferably in an immunodominant region of the nucleocapsid protein, containing a chemically reactive amino acid residue. The modified hepatitis B core protein or its aggregated nucleocapsid protein particles can be pendently linked to a hapten to form a modified nucleocapsid conjugate. Such a conjugate is useful in the preparation of **vaccines** or antibodies. The modified hepatitis B core protein can also be modified to include a T cell epitope.

L5 ANSWER 9 OF 98 USPATFULL
AN 2001:67798 USPATFULL
TI Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
IN Wang, Chang Yi, Cold Spring Harbor, NY, United States
PA United BIomedical, Inc., Hauppauge, NY, United States (U.S. corporation)
PI US 6228987 20010508
AI US 1999-303323 19990430 (9)
RLI Division of Ser. No. US 1998-100414, filed on 20 Jun 1998, now patented, Pat. No. US 6025468
DT Utility
EXNAM Primary Examiner: Fredman, Jeffrey
LREP Morgan & Finnegan, LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1

DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1264
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel peptide immunogens for eliciting antibodies to LHRH comprising artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity. The artificial Th epitopes are covalently linked to LHRH and optionally an immunostimulatory sequence.

L5 ANSWER 10 OF 98 USPATFULL
AN 2001:67794 USPATFULL
TI Human respiratory syncytial virus peptides with antifusogenic and antiviral activities
IN Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PA Trimeris, Inc., Durham, NC, United States (U.S. corporation)
PI US 6228983 20010508
AI US 1995-485264 19950607 (8)
RLI Division of Ser. No. US 1995-470896, filed on 6 Jun 1995
Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994
Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994
Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DT Utility
EXNAM Primary Examiner: Scheiner, Laurie; Assistant Examiner: Parkin, Jeffrey S.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 84 Drawing Figure(s); 83 Drawing Page(s)
LN.CNT 32166
AB The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.

L5 ANSWER 11 OF 98 USPATFULL
AN 2001:67175 USPATFULL
TI GidA1
IN Kallender, Howard, King of Prussia, PA, United States
Reichard, Raymond W., Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6228364 20010508
AI US 1999-360682 19990726 (9)
RLI Division of Ser. No. US 1997-896344, filed on 18 Jul 1997, now patented, Pat. No. US 5994101
DT Utility
EXNAM Primary Examiner: Navarro, Albert
LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides gidA1 polypeptides and DNA (RNA) encoding gidA1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gidA1 polypeptides to screen for antibacterial compounds.

L5 ANSWER 12 OF 98 USPATFULL
AN 2001:55947 USPATFULL
TI Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
IN Krieg, Arthur M., Iowa City, IA, United States
Weiner, George, Iowa City, IA, United States
PA University of Iowa Research Foundation, Iowa City, IA, United States (U.S. corporation)
PI US 6218371 20010417
AI US 1999-286098 19990402 (9)
PRAI US 1998-80729 19980403 (60)
DT Utility
EXNAM Primary Examiner: Yucel, Remy; Assistant Examiner: Zara, Jane
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2746
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to synergistic combinations of immunostimulatory CpG oligonucleotides and immunopotentiating cytokines. In particular, the invention relates to methods of stimulating an immune response using the synergistic combination of compounds and products related thereto.

L5 ANSWER 13 OF 98 USPATFULL
AN 2001:55723 USPATFULL
TI Haemophilus adhesin protein
IN Lingwood, Clifford A., Toronto, Canada
PA HSC Research & Development Limited Partnership, Toronto, Canada (non-U.S. corporation)
PI US 6218147 20010417
AI US 1999-456287 19991208 (9)
RLI Division of Ser. No. US 1996-686528, filed on 26 Jul 1996, now patented, Pat. No. US 6054134
DT Utility
EXNAM Primary Examiner: Graser, Jennifer
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1028
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An adhesin protein which binds specifically to phosphatidylethanolamine (PE), gangliotriaosylceramide (Gg.sub.3) and gangliotetraosylceramide (Gg.sub.4) has been isolated and purified from H. influenzae. Also provided are immunogenic **compositions** and methods of protecting susceptible mammals from diseases caused by bacterial pathogens having the adhesin as a surface protein.

L5 ANSWER 14 OF 98 USPATFULL
AN 2001:51819 USPATFULL
TI Phenylalanyl tRNA synthetase alpha sub-unit from **Chlamydia trachomatis**
IN Brown, James R, Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6214595 20010410
AI US 1999-373958 19990813 (9)
RLI Division of Ser. No. US 1997-899011, filed on 23 Jul 1997, now patented, Pat. No. US 5939298
DT Utility

EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Kerr, Kathleen
LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1249
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides phenylalanyl tRNA synthetase (pheS) pheS polypeptides and DNA (RNA) encoding phenylalanyl tRNA synthetase (pheS) pheS polypeptides and methods for producing such polypeptides from **Chlamydia trachomatis** by recombinant techniques. Also provided are methods for utilizing pheS polypeptides to screen for antibacterial compounds.

L5 ANSWER 15 OF 98 USPATFULL
AN 2001:47842 USPATFULL
TI DNA molecules encoding pgp3 protein from **Chlamydia trachomatis**
IN Ratti, Giulio, Siena, Italy
PA Chiron SpA, Italy (non-U.S. corporation)
PI US 6210968 20010403
AI US 1995-465465 19950605 (8)
RLI Division of Ser. No. US 1994-229980, filed on 19 Apr 1994
DT Utility
EXNAM Primary Examiner: Hobbs, Lisa J.
LREP Blackburn, Robert P.; Harbin, Alisa A.Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an ELISA format.

L5 ANSWER 16 OF 98 USPATFULL
AN 2001:44205 USPATFULL
TI RatA
IN Black, Michael Terence, Chester Springs, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham, plc., United Kingdom (non-U.S. corporation)
PI US 6207647 20010327
AI US 1997-896346 19970718 (8)
DT Utility
EXNAM Primary Examiner: Swart, Rodney P.
LREP Gimmi, Edward R.; Diebert, Thomas S.; King, William T.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1293
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ratA polypeptides and DNA (RNA) encoding ratA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ratA polypeptides to screen for antibacterial compounds.

L5 ANSWER 17 OF 98 USPATFULL
AN 2001:44204 USPATFULL
TI Immunostimulatory nucleic acid molecules

IN Krieg, Arthur M., Iowa City, IA, United States
Kline, Joel, Iowa City, IA, United States
Klinman, Dennis, Potomac, MD, United States
Steinberg, Alfred D., Potomac, MD, United States
PA University of Iowa Research Foundation, Iowa City, IA, United States (U.S. corporation)
Coley Pharmaceutical Group, Inc., Wellesley, MA, United States (U.S. corporation)
The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 6207646 20010327
AI US 1996-738652 19961030 (8)
RLI Continuation of Ser. No. US 1995-386063, filed on 7 Feb 1995
Continuation-in-part of Ser. No. US 1994-276358, filed on 15 Jul 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Martinell, James
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 2680
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed.

L5 ANSWER 18 OF 98 USPATFULL
AN 2001:43720 USPATFULL
TI AspS from **Chlamydia trachomatis**
IN Brown, James R., Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham, plc., United Kingdom (non-U.S. corporation)
PI US 6207162 20010327
AI US 1999-224772 19990104 (9)
RLI Division of Ser. No. US 1997-899244, filed on 23 Jul 1997, now patented, Pat. No. US 5882892
DT Utility
EXNAM Primary Examiner: Duffy, Patricia A.
LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1305
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides aspS polypeptides and DNA (RNA) encoding aspS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing aspS polypeptides to screen for antibacterial compounds.

L5 ANSWER 19 OF 98 USPATFULL
AN 2001:25424 USPATFULL
TI Vectors for the diagnosis and **treatment** of solid tumors including melanoma
IN Pawelek, John M., Hamden, CT, United States
Bermudes, David, Wallingford, CT, United States
Low, Kenneth Brooks, Guilford, CT, United States
PA Yale University, New Haven, CT, United States (U.S. corporation)
PI US 6190657 20010220
AI US 1996-658034 19960604 (8)
RLI Continuation-in-part of Ser. No. US 1995-486422, filed on 7 Jun 1995,

now abandoned
DT Utility
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Sandals, William
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 45 Drawing Figure(s); 38 Drawing Page(s)
LN.CNT 4716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to the isolation and use of super-infective, tumor-specific vectors that are strains of parasites including, but not limited to bacteria, fungi and protists. In certain embodiments the parasites include, but are not limited to, the bacterium Salmonella spp., such as Salmonella typhimurium, the bacterium Mycobacterium avium and the protozoan Leishmania amazonensis. In other embodiments, the present invention is concerned with the isolation of super-infective, tumor-specific, suicide gene-containing strains of parasites for use in **treatment** of solid tumors.

L5 ANSWER 20 OF 98 USPATFULL
AN 2001:22007 USPATFULL
TI HisS from **Chlamydia trachomatis**
IN Brown, James R, Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6187561 20010213
AI US 1998-210009 19981211 (9)
RLI Division of Ser. No. US 1997-899028, filed on 23 Jul 1997, now patented, Pat. No. US 5858720
DT Utility
EXNAM Primary Examiner: Duffy, Patricia A.
LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides hisS polynucleotides which encode hisS polypeptide, polynucleotides related thereto, and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing the hisS polynucleotides and polypeptides to screen for antibacterial compounds and for the detection of pathogens.

L5 ANSWER 21 OF 98 USPATFULL
AN 2001:10718 USPATFULL
TI Antigen carbohydrate compounds and their use in immunotherapy
IN McKenzie, Ian F. C., Victoria, Australia
Apostolopoulos, Vasso, Victoria, Australia
Pietersz, Geoff Allan, Victoria, Australia
PA Austin Research Institute, Victoria, Australia (non-U.S. corporation)
PI US 6177256 20010123
AI US 1998-223043 19981230 (9)
RLI Continuation of Ser. No. US 1997-833807, filed on 9 Apr 1997, now patented, Pat. No. US 5989552 Continuation of Ser. No. US 1994-340711, filed on 16 Nov 1994, now abandoned
PRAI AU 1993-3223 19931226
DT Utility
EXNAM Primary Examiner: Park, Hankyel
LREP Dann Dorfman Herrell and Skillman, P.C.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 1427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Conjugates between one or more repeated subunits of an antigen and a carbohydrate polymer are desired. Also described are immunogenic **vaccines** against disease states which contain the conjugates and methods for inducing cell-mediated immune responses. The conjugates may especially contain polymers of the carbohydrate mannose and one or more repeated subunits of human mucin.

L5 ANSWER 22 OF 98 USPATFULL
AN 2001:7881 USPATFULL
TI Lyss
IN Brown, James R, Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6174714 20010116
AI US 1999-270917 19990316 (9)
RLI Division of Ser. No. US 1997-898780, filed on 23 Jul 1997, now patented, Pat. No. US 5935816
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Kerr, Kathleen
LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides lysS polypeptides and DNA (RNA) encoding lysS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing lysS polypeptides to screen for antibacterial compounds.

L5 ANSWER 23 OF 98 USPATFULL
AN 2001:4512 USPATFULL
TI ratB
IN Black, Michael Terence, Chester Springs, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6171838 20010109
AI US 1997-910313 19970813 (8)
DT Patent
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Tung, Peter P.
LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1361
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ratB polypeptides and DNA (RNA) encoding ratB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ratB polypeptides to screen for antibacterial compounds.

L5 ANSWER 24 OF 98 USPATFULL
AN 2000:174803 USPATFULL
TI Compounds and methods for the **treatment** and diagnosis of chlamydial infection
IN Probst, Peter, Seattle, WA, United States
Bhatia, Ajay, Seattle, WA, United States
Skeiky, Yasir A. W., Seattle, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6166177 20001226
AI US 1998-208277 19981208 (9)
DT Utility
EXNAM Primary Examiner: Navarro, Albert; Assistant Examiner: Lee, Li
LREP Seed Intellectual Property Law Group PLLC
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds and methods for the diagnosis and **treatment** of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydial antigen and DNA sequences encoding such polypeptides. Pharmaceutical **compositions** and **vaccines** comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

L5 ANSWER 25 OF 98 USPATFULL
AN 2000:174122 USPATFULL
TI "Methods and **compositions** for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
IN Neurath, Alexander Robert, New York, NY, United States
Jiang, Shibo, Jackson Heights, NY, United States
Debnath, Asim Kumar, New York, NY, United States
Strick, Nathan, Oceanside, NY, United States
Dow, Gordon Jay, Santa Rosa, CA, United States
PA New York Blood Center, Inc., New York, NY, United States (U.S. corporation)
PI US 6165493 20001226
AI US 1998-175909 19981020 (9)
RLI Continuation-in-part of Ser. No. US 1998-112130, filed on 8 Jul 1998, now patented, Pat. No. US 5985313
PRAI US 1997-62936 19971022 (60)
US 1998-71017 19980113 (60)
DT Utility
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Frishauf, Holtz, Goodman, Langer & Chick, P.C.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 2097
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses or for preventing the transmission of or treating a sexually transmitted bacterial infection by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount or an anti-bacterial amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

L5 ANSWER 26 OF 98 USPATFULL
AN 2000:160601 USPATFULL
TI Immunological tolerance-inducing agent
IN Holmgren, Jan, Vastra Frolunda, Sweden
Czerkinsky, Cecil, Villefranche sur mer, France
PA Duotol AB, Vastra Frolunda, United States (non-U.S. corporation)

PI US 6153203 20001128
AI US 1997-883817 19970627 (8)
RLI Continuation of Ser. No. US 1995-420981, filed on 10 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-184458, filed on 19 Jan 1994, now patented, Pat. No. US 5681571, issued on 28 Oct 1997 which is a continuation-in-part of Ser. No. US 1993-160106, filed on 30 Nov 1993, now abandoned
PRAI CH 1993-9303301 19931008
DT Utility
EXNAM Primary Examiner: Swartz, Rodney P.
LREP Darby & Darby
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1142
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An agent comprising a mucosa-binding molecule linked to a specific microbial antigen is disclosed. Further, a method of inducing immunological tolerance in an individual against a specific microbial antigen, including hapten, which causes an unwanted immune response in said individual, comprising administration by a mucosal route of an immunologically effective amount of an immunological tolerance-inducing agent of the invention to said individual, is described.

L5 ANSWER 27 OF 98 USPATFULL
AN 2000:134872 USPATFULL
TI Method for determining susceptibility to Escherichia coli urinary tract infections, method for diagnosing secretors and nonsecretors, and method and medicament for preventing Escherichia coli urinary tract infections
IN Stapleton, Ann, Seattle, WA, United States
Nudelman, Edward, Seattle, WA, United States
Hakomori, Sen-itiroh, Seattle, WA, United States
Stamm, Walter E., Seattle, WA, United States
Stroud, Mark, Seattle, WA, United States
PA The Regents of the University of Washington, Seattle, WA, United States (U.S. corporation)
The Biomembrane Institute, Seattle, WA, United States (U.S. corporation)
PI US 6130205 20001010
AI US 1995-470045 19950606 (8)
RLI Division of Ser. No. US 1994-352820, filed on 1 Dec 1994, now abandoned which is a division of Ser. No. US 1992-936400, filed on 31 Aug 1992, now patented, Pat. No. US 5374532
DT Utility
EXNAM Primary Examiner: Peselev, Elli
LREP Roylance, Abrams, Berdo & Goodman, L.L.P.
CLMN Number of Claims: 32
ECL Exemplary Claim: 1,2
DRWN 7 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1078
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as Le.sup.a, sialosyl galactosyl-globoside or disialosyl galactosyl-globoside or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, as well as a method for diagnosing secretors and nonsecretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells, vaginal secretions or buccal epithelial cells for the presence or

absence of at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and a method for diagnosing secretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells or vaginal secretions for the presence or absence of at least one of globo H, globo ABO and lacto ABO, and detecting for the presence or absence of the at least one of globo H, globo ABO and lacto ABO and, further, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue, and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E. coli bacterial receptor or bacterial receptor analogue.

L5 ANSWER 28 OF 98 USPATFULL
AN 2000:114100 USPATFULL
TI PyrH of Streptococcus pneumoniae
IN Petit, Chantal Myriam, Wayne, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6111074 20000829
AI US 1998-30978 19980226 (9)
DT Utility
EXNAM Primary Examiner: Navarro, Mark; Assistant Examiner: Lee, Li
LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides pyrH polypeptides and polynucleotides encoding pyrH polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing pyrH polypeptides to screen for antibacterial compounds.

L5 ANSWER 29 OF 98 USPATFULL
AN 2000:113925 USPATFULL
TI DNA **vaccines** for eliciting a mucosal immune response
IN Malone, Robert W., Baltimore, MD, United States
Malone, Jill G., Baltimore, MD, United States
PA University of Maryland, Baltimore, Baltimore, MD, United States (U.S. corporation)
PI US 6110898 20000829
AI US 1997-862632 19970523 (8)
PRAI US 1996-18269 19960524 (60)
DT Utility
EXNAM Primary Examiner: Brusca, John S.; Assistant Examiner: McGarry, Sean
LREP Shanks & Herbert
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention consists of a method for inducing production of a mucosal immune response in a host by administration of an antigen-encoding polynucleotide preparation, comprising DNA or RNA encoding an antigenic epitope to a mucosal inductor site in the mucosal tissue of the host. Naked DNA may be administered directly to mucosa, for instance in saline drops, or in a recombinant gene expression vector. Preferably, the recombinant gene expression vectors are not capable of replication or dessimination. The invention also includes the use of live viral **vaccines** wherein the viruses include immunostimulatory polynucleotides of the invention. According to a preferred method of the

invention, a target protein antigen is administered through its expression by a recombinant gene expression vector.

L5 ANSWER 30 OF 98 USPATFULL
AN 2000:109527 USPATFULL
TI Synthetic peptide **vaccines** for foot-and-mouth disease
IN Wang, Chang Yi, Cold Spring Harbor, NY, United States
Shen, Ming, Flushing, NY, United States
PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)
PI US 6107021 20000822
AI US 1998-100600 19980620 (9)
DT Utility
EXNAM Primary Examiner: Salimi, Ali
LREP Morgan & Finnegan, LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 3425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of a peptide **composition** as an immunogen, with each peptide contained therein comprising a target antigenic site derived from the VP1 capsid protein of Foot-and-Mouth Disease Virus (FMDV). The antigenic site is covalently linked to a helper T cell epitope and, preferably, to other immunostimulatory sequences, preferably by conventional peptide bond(s) through direct synthesis, for the prevention of FMDV infection and eradication of Foot-and-Mouth Disease (FMD). More particularly, the present invention relates to the use of such peptide **composition** as an immunogen to elicit the production in animals including swine, cattle, sheep, goats and susceptible wild species, of high titer polyclonal antibodies that can effectively neutralize, in vitro, multiple strains or serotypes of FMDV, and to the use of such **composition** as a **vaccine** to prevent, and/or reduce the incidence of, FMDV infection regardless of serotype, and thus affect the eradication of FMDV. The present invention also relates to the peptides used in the **compositions**, and to immunoassays and/or diagnostic kits containing one or more of these peptides, and methods of diagnosing FMDV in mammals using such materials.

L5 ANSWER 31 OF 98 USPATFULL
AN 2000:98204 USPATFULL
TI **Chlamydia trachomatis** serotype D proteins
IN Ratti, Givlio, Siena, Italy
Comanducci, Maurizio, Siena, Italy
Tecce, Mario F., Siena, Italy
Giuliani, Marzia M., Siena, Italy
PA Sclavo SpA, Italy (non-U.S. corporation)
PI US 6096519 20000801
AI US 1997-969644 19971113 (8)
RLI Division of Ser. No. US 1995-467152, filed on 6 Jun 1995, now abandoned which is a division of Ser. No. US 1995-444189, filed on 18 May 1995 which is a continuation of Ser. No. US 1994-180528, filed on 12 Jan 1994, now abandoned which is a division of Ser. No. US 1992-991512, filed on 17 Dec 1992, now abandoned which is a continuation of Ser. No. US 1991-661820, filed on 28 Feb 1991, now abandoned
PRAI IT 1991-MI314 19910207
DT Utility
EXNAM Primary Examiner: Chin, Christopher L.; Assistant Examiner: Swartz, Rodney P.
LREP Trujillo, Doreen Y.; Harbin, Alisa A.; Blackburn, Robert P.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 1686

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A plasmid isolated from Clamydia trachomatis is described, which comprises 8 genes encoding proteins useful in the formulation of **vaccines** or diagnostic test for determining the bacterium or specific antibodies generated during C. trachomatis infections; in particular the recombinant fusion MS2-pgp3D protein is described comprising polypeptidic sequences encoded by pCT and immunogenic in the course of infections in man. A method for preparing said protein in E. coli further described.

L5 ANSWER 32 OF 98 USPATFULL
AN 2000:91543 USPATFULL
TI Peptide **composition** for prevention and **treatment** of HIV infection and immune disorders
IN Wang, Chang Yi, Cold Spring Harbor, NY, United States
PA United Biomedical Inc., Hauppauge, NY, United States (U.S. corporation)
PI US 6090388 20000718
AI US 1998-100409 19980620 (9)
DT Utility
EXNAM Primary Examiner: Saunders, David; Assistant Examiner: Tung, Mary B.
LREP Morgan & Finnegan LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 3077
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides peptides comprising a sequence homologous to a portion of the CDR-2 like domain of CD4, covalently linked to a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the production in mammals of high titer polyclonal auto-antibodies, which are specific to CD4 surface complex. These auto-antibodies prevent binding of HIV viral particles to CD4+ cells. The peptides are useful in pharmaceutical **compositions**, to provide an immunotherapy for HIV infection and to protect against HIV infection.

L5 ANSWER 33 OF 98 USPATFULL
AN 2000:80733 USPATFULL
TI Immunostimulating and **vaccine compositions** employing saponin analog adjuvants and uses thereof
IN Marciani, Dante J., Brimingham, AL, United States
PA Galenica Pharmaceuticals, Inc., Frederick, MD, United States (U.S. corporation)
PI US 6080725 20000627
AI US 1999-290606 19990413 (9)
RLI Continuation-in-part of Ser. No. US 1998-81647, filed on 20 May 1998, now patented, Pat. No. US 5977081
PRAI US 1997-47129 19970520 (60)
US 1998-80389 19980402 (60)
DT Utility
EXNAM Primary Examiner: Lee, Howard C.
LREP Sterne, Kessler, Goldstein & Fox, P.L.L.C.
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to **vaccines** comprising (1) one or more bacterial, viral or tumor-associated antigens; and (2) one or more saponin-lipophile conjugate in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carboxyl group present on the 3-O-glucuronic acid of the triterpene

saponin. The attachment of a lipophile moiety to the 3-O-glucuronic acid of a saponin such as Quillaja desacylsaponin, lucyoside P, or saponin from Gypsophila, Saponaria and Acanthophyllum enhances their adjuvant effects on humoral and cell mediated immunity. Additionally, the attachment of a lipophile moiety to the 3-O-glucuronic acid residue of non- or des-acylsaponin yields a saponin analog that is easier to purify, less toxic, chemically more stable, and possesses equal or better adjuvant properties than the original saponin.

L5 ANSWER 34 OF 98 USPATFULL
AN 2000:67442 USPATFULL
TI Formulation for use in the prevention of pathogen induced diseases including HIV and HSV
IN Bergeron, Michel G., Sillery, Canada
Desormeaux, Andre, Neufchatel, Canada
Tremblay, Michel, Neufchatel, Canada
PA Infectio Recherche, Inc., Sainte Foy, Canada (non-U.S. corporation)
PI US 6068851 20000530
WO 9742962 19971120
AI US 1999-51300 19990113 (9)
WO 1997-CA319 19970509
19990113 PCT 371 date
19990113 PCT 102(e) date
PRAI US 1996-17106 19960509 (60)
DT Utility
EXNAM Primary Examiner: Stucker, Jeffrey
LREP Godfrey & Kahn, S.C.
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 763
AB This invention relates to formulations comprising film-forming components capable of forming per se a physical barrier to pathogens. Thermoreversible gels such as poloxamers are particularly preferred for that use. The film-forming formulations may further comprise microbicides, spermicides or any other drug, which choice is guided by the pathogen, organism or the disease to be inactivated or treated. The formulations are therefore efficient as a physical, and optionally, as a chemical or pharmacological barrier as well as usable as a sustained drug-release system at the locus of administration. A part of the drug may also be entrapped in liposomes or other drug carriers. These formulations are intended for use in the prevention of sexually transmitted diseases, as well as in the **treatment** of infections, cancer, inflammation or any disease or state which requires a pharmacological **treatment**. Formulations are applicable to mucosae, skin and eye, for example.

L5 ANSWER 35 OF 98 USPATFULL
AN 2000:61721 USPATFULL
TI Recombinant human IGA-J. chain dimer
IN Capra, J. Donald, Dallas, TX, United States
Hexham, Jonathan M., Dallas, TX, United States
Carayannopoulos, Leon N., St Louis, MO, United States
Max, Edward E., Bethesda, MD, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 6063905 20000516
AI US 1997-779597 19970107 (8)
DT Utility
EXNAM Primary Examiner: Eyler, Yvonne
LREP Arnold, White & Durkee
CLMN Number of Claims: 102

ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2003
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are **compositions** and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.

L5 ANSWER 36 OF 98 USPATFULL
AN 2000:54215 USPATFULL
TI CysS
IN Brown, James R, Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6057432 20000502
AI US 1997-898977 19970723 (8)
DT Utility
EXNAM Primary Examiner: Scheiner, Laurie
LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1469
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides cysS polypeptides and DNA (RNA) encoding cysS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing cysS polypeptides to screen for antibacterial compounds.

L5 ANSWER 37 OF 98 USPATFULL
AN 2000:50384 USPATFULL
TI Haemophilus adhesin protein
IN Lingwood, Clifford A., Toronto, Canada
PA HSC Research & Development Limited, Ontario, Canada (non-U.S. corporation)
PI US 6054134 20000425
AI US 1996-686528 19960726 (8)
DT Utility
EXNAM Primary Examiner: Chin, Christopher L.; Assistant Examiner: Graser, Jennifer
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1141
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An adhesin protein which binds specifically to phosphatidylethanolamine (PE), gangliotriaosylceramide (Gg.sub.3) and gangliotetraosylceramide (Gg.sub.4) has been isolated and purified from H. influenzae. Also provided are immunogenic **compositions** and methods of protecting susceptible mammals from diseases caused by bacterial pathogens having the adhesin as a surface protein.

L5 ANSWER 38 OF 98 USPATFULL
AN 2000:34416 USPATFULL
TI Human cytomegalovirus DNA sequences
IN Spaete, Richard, Belmont, CA, United States
Cha, Tai-An, San Ramon, CA, United States
PA Aviron, Mountain View, CA, United States (U.S. corporation)

PI US 6040170 20000321
AI US 1999-253682 19990218 (9)
RLI Division of Ser. No. US 1997-926922, filed on 10 Sep 1997, now patented, Pat. No. US 5925751 which is a division of Ser. No. US 1995-414926, filed on 31 Mar 1995, now patented, Pat. No. US 5721354
DT Utility
EXNAM Primary Examiner: Park, Hankyel
LREP Cserr, Luann; Dunn, Tracy
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 53 Drawing Page(s)
LN.CNT 3110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and **compositions** for detecting HCMV infections and in immunogenic **compositions** for preventing HCMV infections.

L5 ANSWER 39 OF 98 USPATFULL
AN 2000:28125 USPATFULL
TI Nucleic acids encoding myocardial peptides
IN Bachmaier, Kurt, Toronto, Canada
Hessel, Andrew John, Toronto, Canada
Neu, Nickolaus, Innsbruck, Austria
Penninger, Josef Martin, Toronto, Canada
PA Amgen Canada Inc., Mississauga, Canada (non-U.S. corporation)
PI US 6034230 20000307
AI US 1999-303862 19990503 (9)
RLI Continuation of Ser. No. US 1998-133774, filed on 12 Aug 1998
DT Utility
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: De Cloux, Amy
LREP Oleski, Nancy A.; Odre, Steven M.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1,2,3
DRWN No Drawings
LN.CNT 1405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.

L5 ANSWER 40 OF 98 USPATFULL
AN 2000:24473 USPATFULL
TI Immunoassays for detecting chlamydial antigens or antibodies thereto using recombinant or synthetic major outer membrane protein polypeptides as substitute antigens
IN Agabian, Nina, San Francisco, CA, United States
Stephens, Richard, Oakland, CA, United States
Kuo, Cho-Chou, Seattle, WA, United States
Mullenbach, Guy, Oakland, CA, United States
PA Washington Research Foundation, Seattle, WA, United States (U.S. corporation)
PI US 6030799 20000229
AI US 1995-466152 19950606 (8)
RLI Division of Ser. No. US 1993-144095, filed on 28 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-691639, filed on 25 Apr 1991, now abandoned which is a continuation of Ser. No. US 1986-818523, filed on 13 Jan 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-692001, filed on 14 Jan 1985, now abandoned
DT Utility
EXNAM Primary Examiner: Minnifield, Nita; Assistant Examiner: Baskar, Padma
LREP Townsend and Townsend and Crew
CLMN Number of Claims: 21
ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 823
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and **compositions** are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of **Chlamydia trachomatis**. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a .beta.-glactosidase promoter and terminator is provided. Recombinant phage .lambda.gtl1/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.

L5 ANSWER 41 OF 98 USPATFULL
AN 2000:18553 USPATFULL
TI Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
IN Wang, Chang Yi, Cold Spring Harbor, NY, United States
PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)
PI US 6025468 20000215
AI US 1998-100414 19980620 (9)
DT Utility
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Pelley, Ronald
LREP Morgan & Finnegan, LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 2155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to novel peptide immunogens for eliciting antibodies to LHRH comprising artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity. The artificial Th epitopes are covalently linked to LHRH and optionally an immunostimulatory seqence.

L5 ANSWER 42 OF 98 USPATFULL
AN 2000:18049 USPATFULL
TI Recombinant avirulent immunogenic S typhi having rpos positive phenotype
IN Curtiss, III, Roy, St. Louis, MO, United States
Nickerson, Cheryl A., Chesterfield, MO, United States
PA Washington University, St. Louis, MO, United States (U.S. corporation)
PI US 6024961 20000215
AI US 1997-970789 19971114 (8)
DT Utility
EXNAM Primary Examiner: Mosher, Mary E.
LREP Howell & Haferkamp, L.C.
CLMN Number of Claims: 41
ECL Exemplary Claim: 1,39
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 2837
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Avirulent immunogenic Salmonella enterica serotype Typhi and methods therefor are disclosed. The Salmonella have an RpoS.sup.+ phenotype, an inactivating mutation in one or more genes which renders the microbe avirulent, and a recombinant gene capable of expressing a desired protein. The Salmonella are avirulent and have high immunogenicity so that they can be used in **vaccines** and as delivery vehicles for the desired antigen. Also disclosed are methods for preparing the Salmonella and **vaccine** delivery vehicles therefor.

L5 ANSWER 43 OF 98 USPATFULL
AN 2000:7077 USPATFULL

TI Method for inducing a systemic immune response to an antigen
IN See, Jackie R., Reno, NV, United States
See, Darryl M., Laguna Niguel, CA, United States
PA Bio-Sphere Technology, Inc., Reno, NV, United States (U.S. corporation)
PI US 6015576 20000118
AI US 1997-920374 19970829 (8)
RLI Continuation of Ser. No. WO 1997-US4634, filed on 24 Mar 1997 which is a continuation-in-part of Ser. No. US 1996-621802, filed on 22 Mar 1996, now abandoned
DT Utility
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Christie, Parker & Hale, LLP
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 982
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is provided for inducing a systemic immune response to an antigen in a mammal. The method comprises orally administering lyophilized multilamellar liposomes containing the antigen. The liposomes have a size of from 20 nm to 20 microns. The antigen-containing liposomes are absorbed in the Peyer's patches of the gut. Sufficient antigen-containing liposomes are taken up by macrophages in the Peyer's patches to induce a systemic immune response to the antigen.

L5 ANSWER 44 OF 98 USPATFULL
AN 1999:163458 USPATFULL
TI DNA encoding **Chlamydia trachomatis** isoleucyl tRNA synthetase polypeptides
IN Brown, James R, Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6001602 19991214
AI US 1997-898978 19970723 (8)
DT Utility
EXNAM Primary Examiner: Caputa, Anthony C.; Assistant Examiner: Navarro, Mark
LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ileS polypeptides and DNA (RNA) encoding ileS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ileS polypeptides to screen for antibacterial compounds.

L5 ANSWER 45 OF 98 USPATFULL
AN 1999:155485 USPATFULL
TI DNA encoding gidA1 polypeptides
IN Kallender, Howard, King of Prussia, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5994101 19991130
AI US 1997-896344 19970718 (8)
DT Utility
EXNAM Primary Examiner: Caputa, Anthony C.; Assistant Examiner: Navarro, Mark
LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 1563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides gidA1 polypeptides and DNA (RNA) encoding gidA1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gidA1 polypeptides to screen for antibacterial compounds.

L5 ANSWER 46 OF 98 USPATFULL
AN 1999:150987 USPATFULL
TI HisS polypeptides from **Chlamydia trachomatis**
IN Brown, James R, Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5989884 19991123
AI US 1998-210124 19981211 (9)
RLI Division of Ser. No. US 1997-899028, filed on 23 Jul 1997, now patented, Pat. No. US 5858720
DT Utility
EXNAM Primary Examiner: Duffy, Patricia A.
LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides hisS polypeptides and DNA (RNA) encoding hisS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing hisS polypeptides to screen for antibacterial compounds.

L5 ANSWER 47 OF 98 USPATFULL
AN 1999:150655 USPATFULL
TI Antigen carbohydrate compounds and their use in immunotherapy
IN McKenzie, Ian F. C., Victoria, Australia
Pietersz, Geoff Allen, Victoria, Australia
Apostolopoulos, Vasso, Victoria, Australia
PA Austin Research Institute, Victoria, Australia (non-U.S. corporation)
PI US 5989552 19991123
AI US 1997-833807 19970409 (8)
RLI Continuation of Ser. No. US 1994-340711, filed on 16 Nov 1994, now abandoned
PRAI AU 1993-3223 19931224
DT Utility
EXNAM Primary Examiner: Knode, Marian C.; Assistant Examiner: Williams, Jay F.
LREP Dann, Dorfman, Herrell And Skillman
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 1551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Conjugates between one or more repeated subunits of an antigen and a carbohydrate polymer are desired. Also described are immunogenic **vaccines** against disease states which contain the conjugates and methods for inducing cell-mediated immune responses. The conjugates may especially contain polymers of the carbohydrate mannose and one or more repeated subunits of human mucin.

L5 ANSWER 48 OF 98 USPATFULL
AN 1999:146013 USPATFULL
TI Method for decreasing the frequency of transmission of viral infections using cellulose acetate phthalate or hydroxypropyl methylcellulose

phthalate excipients
IN Neurath, Alexander Robert, New York, NY, United States
Debnath, Asim Kumar, Fort Lee, NJ, United States
Jiang, Shibo, New York, NY, United States
Strick, Nathan, Oceanside, NY, United States
Dow, Gordon Jay, Santa Rosa, CA, United States
PA New York Blood Center, Inc., New York, NY, United States (U.S. corporation)
PI US 5985313 19991116
AI US 1998-112130 19980708 (9)
PRAI US 1997-62936 19971022 (60)
US 1998-71017 19980113 (60)
DT Utility
EXNAM Primary Examiner: Azpuru, Carlos
LREP Frishauf, Holtz, Goodman, Langer & Chick, P.C.
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

L5 ANSWER 49 OF 98 USPATFULL
AN 1999:145975 USPATFULL
TI .beta.-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
IN Neurath, Alexander Robert, New York, NY, United States
Debnath, Asim Kumar, New York, NY, United States
Jiang, Shibo, Jackson Heights, NY, United States
PA New York Blood Center, New York, NY, United States (U.S. corporation)
PI US 5985275 19991116
AI US 1995-537245 19950929 (8)
RLI Continuation-in-part of Ser. No. US 1995-492940, filed on 21 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-420573, filed on 12 Apr 1995, now abandoned
DT Utility
EXNAM Primary Examiner: Tsang, Cecillia J.; Assistant Examiner: Delaney, Patrick
LREP Frishauf, Holtz, Goodman, Langer & Chick, P.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 2532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A **composition** is provided which comprises a protein or peptide containing lysines, wherein at least one of the lysines and/or the N-terminal amino group of the protein or peptide, such as casein, .beta.-lactoglobulin, powdered milk or whey, is modified by contact with an aromatic acid anhydride compound, such as trimellitic anhydride, trimellitic anhydride chloride or 3-hydroxyphthalic anhydride. Additionally a **composition** is provided wherein a protein or peptide containing arginines is modified by an arginine modifying agent containing at least one carboxyl group, such as p-carboxyphenylglyoxal. The **compositions** are capable of binding to CD4 cell receptors, such as the HIV-1 or HIV-2 binding site on CD4 cell receptors. The **compositions** are thus useful for the prevention of HIV-1 or

HIV-2 infection, especially by local administration.

L5 ANSWER 50 OF 98 USPATFULL
AN 1999:121567 USPATFULL
TI Deformylase
IN Lonetto, Michael Arthur, Collegeville, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5962666 19991005
AI US 1997-932142 19970916 (8)
DT Utility
EXNAM Primary Examiner: Minnifield, Nita
LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides def polypeptides and DNA (RNA) encoding def polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing def polypeptides to screen for antibacterial compounds.

L5 ANSWER 51 OF 98 USPATFULL
AN 1999:121537 USPATFULL
TI Peptides capable of modulating inflammatory heart disease
IN Bachmaier, Kurt, Toronto, Canada
Hessel, Andrew John, Toronto, Canada
Neu, Nickolaus, Innsbruck, Austria
Penninger, Josef Martin, Toronto, Canada
PA Amgen Canada Inc., Mississauga, Canada (non-U.S. corporation)
PI US 5962636 19991005
AI US 1998-133774 19980812 (9)
DT Utility
EXNAM Primary Examiner: Eisenschenk, Frank C.; Assistant Examiner: Pelley, Ronald P
LREP Oleski, Nancy A.; Levy, Ron K.; Odre, Steven M.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.

L5 ANSWER 52 OF 98 USPATFULL
AN 1999:120887 USPATFULL
TI Stable pura vectors and uses therefor
IN Brey, Robert N., Rochester, NY, United States
Fulginiti, James P., Canandaigua, NY, United States
Anilionis, Algis, Pittsford, NY, United States
PA Praxis Biologics, Inc., West Henrietta, NJ, United States (U.S. corporation)
PI US 5961983 19991005
AI US 1995-448907 19950524 (8)
RLI Division of Ser. No. US 1995-380297, filed on 30 Jan 1995 which is a continuation of Ser. No. US 1994-204903, filed on 2 Mar 1994, now abandoned which is a continuation of Ser. No. US 1991-695706, filed on 3 May 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
LREP Hamilton, Brook, Smith & Reynolds, P.C.
CLMN Number of Claims: 32

ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention pertains to a complementation system for the selection and maintenance of expressed genes in bacterial hosts. The invention provides stable vectors which can be selected and maintained by complementation of chromosomal deletion mutations of purA (adenylosuccinate synthetase), obviating the use of antibiotic resistance genes. This system is useful in production organisms during fermentation and in live **vaccine** bacteria, such as attenuated Salmonella typhi. This system allows for selection of chromosomal integrants and for selection and stable plasmid maintenance in the vaccinated host without application of external selection pressure.

L5 ANSWER 53 OF 98 USPATFULL
AN 1999:113367 USPATFULL
TI Dual carrier immunogenic construct
IN Mond, James J., Potomac, MD, United States
Lees, Andrew, Baltimore, MD, United States
PA Henry Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)
PI US 5955079 19990921
AI US 1995-468359 19950606 (8)
RLI Continuation of Ser. No. US 1995-402565, filed on 13 Mar 1995, now patented, Pat. No. US 5585100 which is a continuation of Ser. No. US 1993-126017, filed on 24 Sep 1993, now abandoned which is a continuation of Ser. No. US 1992-834067, filed on 11 Feb 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Shaver, Jennifer
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 74
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1324
AB A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, **treatment**, and prevention of diseases.

L5 ANSWER 54 OF 98 USPATFULL
AN 1999:109999 USPATFULL
TI Methods for preventing the transmission of or treating patients infected with herpesvirus
IN Neurath, Alexander Robert, New York, NY, United States
Debnath, Asim Kumar, New York, NY, United States
Jiang, Shibo, Jackson Heights, NY, United States
PA New York Blood Center, New York, NY, United States (U.S. corporation)
PI US 5952009 19990914
AI US 1996-703925 19960828 (8)
RLI Continuation-in-part of Ser. No. US 1996-618830, filed on 20 Mar 1996, now abandoned
DT Utility
EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Delaney, Patrick R.
LREP Frishauf, Holtz, Goodman, Langer & Chick, P.C.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1382
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of preventing the transmission of or treating herpesvirus, such as herpes simplex virus infection, or **Chlamydia trachomatis** comprising administering to a patient a **composition** which comprises: (i) a protein or peptide containing lysines and an N-terminal amino group, wherein at least one of the lysines or the N-terminal amino group of the protein or peptide, such as casein, .beta.-lactoglobulin, powdered milk or whey, is modified by contact with an aromatic acid anhydride compound, such as trimellitic anhydride, trimellitic anhydride chloride or 3-hydroxyphthalic anhydride and/or (ii) a protein or peptide containing arginines, which is modified by an arginine modifying agent containing at least one carboxyl group, such as p-carboxyphenylglyoxal.

L5 ANSWER 55 OF 98 USPATFULL
AN 1999:102667 USPATFULL
TI Method and system for enhanced production of commercially important exoproteins in gram-positive bacteria
IN Kontinen, Vesa, Helsinki, Finland
Sarvas, Matti, Helsinki, Finland
PA The Finnish National Public Health Institute, Helsinki, Finland (non-U.S. corporation)
PI US 5945278 19990831
AI US 1998-108920 19980701 (9)
RLI Division of Ser. No. US 1996-507391, filed on 8 Jul 1996, now patented, Pat. No. US 5780261, issued on 14 Jul 1998 which is a continuation-in-part of Ser. No. US 24154
DT Utility
EXNAM Primary Examiner: Guzo, David
LREP Meyer, Esq., Virginia H.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method and expression system for enhancing secretion of hyperproduced homologous and heterologous exoproteins in gram-positive bacteria such as Bacillus sp. The method and system comprise overproduction of PrsA protein in a gram-positive bacterial host also overproducing at least one exoprotein of interest. Use of the method and system of the invention results in greatly enhanced secretion of the synthesized exoproteins into the growth medium. Once in the growth medium these secreted exoproteins can be recovered and purified in a straightforward manner.

L5 ANSWER 56 OF 98 USPATFULL
AN 1999:96249 USPATFULL
TI DNA encoding phenylalanyl tRNA synthetase alpha sub-unit from chlamydi a trachomatis
IN Brown, James R, Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5939298 19990817
AI US 1997-899011 19970723 (8)
DT Utility
EXNAM Primary Examiner: Hobbs, Lisa
LREP King, William T.; Gimmi, Edward R.; Jackson, Arthur E.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1343
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides pheS polypeptides and DNA (RNA) encoding pheS

polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing pheS polypeptides to screen for antibacterial compounds.

L5 ANSWER 57 OF 98 USPATFULL
AN 1999:92533 USPATFULL
TI **Chlamydia trachomatis** lysS polynucleotides
IN Brown, James R., Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5935816 19990810
AI US 1997-898780 19970723 (8)
DT Utility
EXNAM Primary Examiner: Campell, Bruce R.; Assistant Examiner: Priebe, Scott D.
LREP King, William T.; Gimmi, Edward R.; Jackson, Arthur E.
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides lysS polypeptides and DNA (RNA) encoding lysS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing lysS polypeptides to screen for antibacterial compounds.

L5 ANSWER 58 OF 98 USPATFULL
AN 1999:81942 USPATFULL
TI Human cytomegalovirus DNA sequences
IN Spaete, Richard, Belmont, CA, United States
Cha, Tai-An, San Ramon, CA, United States
PA Aviron, Mountain View, CA, United States (U.S. corporation)
PI US 5925751 19990720
AI US 1997-926922 19970910 (8)
RLI Division of Ser. No. US 1995-414926, filed on 31 Mar 1995, now patented, Pat. No. US 5721354
DT Utility
EXNAM Primary Examiner: Stucker, Jeffrey; Assistant Examiner: Park, Hankyel T.
LREP Cserr, Luann; Dunn, Tracy
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 53 Drawing Page(s)
LN.CNT 2757
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and **compositions** for detecting HCMV infections and in immunogenic **compositions** for preventing HCMV infections.

L5 ANSWER 59 OF 98 USPATFULL
AN 1999:75520 USPATFULL
TI Stable purA vectors and uses therefor
IN Brey, Robert N., Rochester, NY, United States
Fulginiti, James P., Canandaigua, NY, United States
Anilionis, Algis, Pittsford, NY, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 5919663 19990706
AI US 1995-380297 19950130 (8)
RLI Continuation of Ser. No. US 1994-204903, filed on 2 Mar 1994, now abandoned which is a continuation of Ser. No. US 1991-695706, filed on 3 May 1991, now abandoned
DT Utility

EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.
LREP Hamilton, Brook, Smith & Reynolds,P.C.
CLMN Number of Claims: 41
ECL Exemplary Claim: 8
DRWN 13 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention pertains to a complementation system for the selection and maintenance of expressed genes in bacterial hosts. The invention provides stable vectors which can be selected and maintained by complementation of chromosomal deletion mutations of purA (adenylosuccinate synthetase), obviating the use of antibiotic resistance genes. This system is useful in production organisms during fermentation and in live **vaccine** bacteria, such as attenuated Salmonella typhi. This system allows for selection of chromosomal integrants and for selection and stable plasmid maintenance in the vaccinated host without application of external selection pressure.

L5 ANSWER 60 OF 98 USPATFULL
AN 1999:75477 USPATFULL
TI Heat shock protein HSP72 of Streptococcus pneumoniae
IN Brodeur, Bernard R., Sillery, Canada
Martin, Denis, St.-Augustin, Canada
Hamel, Josee, Sillery, Canada
PA Biochem Vaccines Inc., Ste-Foy, Canada (non-U.S. corporation)
PI US 5919620 19990706
AI US 1995-472534 19950607 (8)
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Swartz, Rodney P.
LREP Foley & Lardner
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A heat shock protein of Streptococcus pneumoniae named HSP72 and immunologically related polypeptides, the nucleotide and derived amino acid sequences of HSP72 (SEQ ID NO:4; SEQ ID NO:5), antibodies that bind to HSP72, and recombinant DNA methods for the production of HSP72 and immunologically related polypeptides. The polypeptides, DNA sequences and antibodies of this invention provide new means for the diagnosis, prevention and/or **treatment** of disease.

L5 ANSWER 61 OF 98 USPATFULL
AN 1999:43372 USPATFULL
TI Methods of culturing and assaying a virus in a specimen
IN Huang, Yung T., Richmond Heights, OH, United States
PA University Hospitals of Cleveland, Cleveland, OH, United States (U.S. corporation)
PI US 5891624 19990406
AI US 1997-868091 19970603 (8)
RLI Division of Ser. No. US 1995-578189, filed on 29 Dec 1995
DT Utility
EXNAM Primary Examiner: Smith, Lynette F.; Assistant Examiner: Nelson, Brett
LREP Renner, Otto, Boisselle & Sklar, P.L.L.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a method for culturing a virus including the steps of (A) providing cells from a cell line susceptible to infection by the virus and a specimen; (B) treating the cells with a compound of

formula RC(O)Q, wherein Q is R, OR, OX or X, each R is independently hydrogen or a hydrocarbyl group containing 1 to about 10 carbon atoms and wherein X is hydrogen or a cation; (C) inoculating the treated cells with the specimen; and (D) incubating the inoculated cells to allow viral growth to proceed.

L5 ANSWER 62 OF 98 USPATFULL
AN 1999:33800 USPATFULL
TI ASPS
IN Brown, James R, Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA Smithkline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5882892 19990316
AI US 1997-899244 19970723 (8)
DT Utility
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Duffy, Patricia A.
LREP Gimmi, Edward R.; King, William T.; Jackson, Arthur E.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides aspS polypeptides and DNA (RNA) encoding aspS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing aspS polypeptides to screen for antibacterial compounds.

L5 ANSWER 63 OF 98 USPATFULL
AN 1999:33558 USPATFULL
TI Peptide compounds
IN Toth, Istvan, Middlesex, United Kingdom
Gibbons, William Anthony, Kennington, United Kingdom
PA The School of Pharmacy, University of London, United Kingdom (non-U.S. corporation)
PI US 5882645 19990316
WO 9402506 19940203
AI US 1995-374560 19950313 (8)
WO 1993-GB1558 19930723
19950313 PCT 371 date
19950313 PCT 102(e) date
PRAI GB 1992-15780 19920724
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Ashton, Rosemary
LREP Ostrolenk, Faber, Gerb & Soffen, LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 1491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synthetic peptides are widely used to generate antibodies. To induce high antibody response, it is known to conjugate the peptide to a carrier protein (e.g. KLH, BSA) or to incorporate it into polylysine to form a multiple antigenic peptide. Anchors may be built in which are based on fatty acids. According to the invention there is provided a novel lipidic amino acid based anchor system which can maximally enhance the antigenicity of a short synthetic peptide. These novel compounds are entirely peptide-based and may therefore be produced automatically by some step wise peptide synthesis, preferably solid phase step wise peptide synthesis. According to the invention there is also provided such a process.

L5 ANSWER 64 OF 98 USPATFULL
AN 1999:4385 USPATFULL
TI Hiss
IN Brown, James R., Berwyn, PA, United States
Lawlor, Elizabeth J, Malvern, PA, United States
Reichard, Raymond W, Quakertown, PA, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5858720 19990112
AI US 1997-899028 19970723 (8)
DT Utility
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Duffy, Patricia A.
LREP Gimmi, Edward R.; King, William T.; Jackson, Arthur E.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides hisS polypeptides and DNA (RNA) encoding hisS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing hisS polypeptides to screen for antibacterial compounds.

L5 ANSWER 65 OF 98 USPATFULL
AN 1999:1233 USPATFULL
TI Ichimeric papillomavirus-like particles
IN Lowy, Douglas R., Bethesda, MD, United States
Schiller, John T., Silver Spring, MD, United States
Greenstone, Heather, Silver Spring, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5855891 19990105
AI US 1997-781084 19970109 (8)
RLI Division of Ser. No. US 1994-319467, filed on 6 Oct 1994, now patented, Pat. No. US 5618536 which is a continuation-in-part of Ser. No. US 1993-32869, filed on 16 Mar 1993, now patented, Pat. No. US 5437951 which is a continuation-in-part of Ser. No. US 1992-941371, filed on 3 Apr 1992
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapura; Assistant Examiner: Park, Hankyel T.
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a papillomavirus-like particle having conformational epitopes comprising a papillomavirus L1 fusion product and, optionally, a papillomavirus L2 product; and related DNA molecules, host cells, and methods.

L5 ANSWER 66 OF 98 USPATFULL
AN 1998:156922 USPATFULL
TI Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
IN Lees, Andrew, Silver Spring, MD, United States
PA Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)
PI US 5849301 19981215
AI US 1995-482666 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-408717, filed on 22 Mar 1995, now patented, Pat. No. US 5651971 which is a continuation-in-part of

Ser. No. US 1993-124491, filed on 22 Sep 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapura
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 2085
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a process for producing an immunogenic construct comprising activating at least one first carbohydrate-containing moiety with CDAP, CTEA or pNPC, and covalently joining the activated first moiety to a second moiety. Preferably, the first moiety is a polysaccharide and the second moiety is a protein. Immunogenic constructs are prepared by this process using either direct or indirect conjugation of the first and second moieties.

L5 ANSWER 67 OF 98 USPATFULL
AN 1998:150467 USPATFULL
TI Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for **vaccines**
IN Ladd, Anna Efim, Brooklyn, NY, United States
Wang, Chang Yi, Cold Spring Harbor, NY, United States
Zamb, Timothy Joseph, Stony Brook, NY, United States
PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)
PI US 5843446 19981201
AI US 1995-488351 19950607 (8)
RLI Division of Ser. No. US 1995-446692, filed on 5 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-229275, filed on 14 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-57166, filed on 27 Apr 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Smith, Lynette F.
LREP Morgan & Finnegan, LLP
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 39 Drawing Figure(s); 37 Drawing Page(s)
LN.CNT 4050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or **treatment** of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasin domain which acts as a general immune stimulator.

In another aspect this invention relates to immunogenic synthetic peptides having an invasin domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, **Chlamydia** MOMP peptides, HIV V3 peptides and Plasmodium berghei.

L5 ANSWER 68 OF 98 USPATFULL
AN 1998:147025 USPATFULL
TI **Vaccine** comprising anti-idiotypic antibody to **chlamydia** GLXA and process
IN MacDonald, Alex Bruce, Amherst, MA, United States

An, Ling-Ling, La Jolla, CA, United States
Sutton-Stuart, Elizabeth, Amherst, MA, United States
Whittum-Hudson, Judith A., Elkton, MD, United States
PA Johns Hopkins University, United States (U.S. corporation)
University of Massachusetts, United States (U.S. corporation)
PI US 5840297 19981124
AI US 1993-34572 19930319 (8)
DT Utility
EXNAM Primary Examiner: Loring, Susan A.
LREP Cook, Paul J.
CLMN Number of Claims: 17
ECL Exemplary Claim: 5
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A genus specific **chlamydia vaccine** is provided which comprises an anti-idiotype antibody capable of producing in an animal an anti-anti-idiotypic antibody which recognizes a glycoplipid exoantigen (GLXA) of **chlamydia**. The **vaccine** is produced by producing an idiotypic antibody to GLXA which, in turn, is utilized t produce the anti-idiotypic antibody comprising the **vaccine**.

L5 ANSWER 69 OF 98 USPATFULL
AN 1998:124386 USPATFULL
TI **Chlamydia** major outer membrane protein
IN Agabian, Nina, San Francisco, CA, United States
Stephens, Richard, Oakland, CA, United States
Kuo, Cho-Chou, Seattle, WA, United States
Mullenbach, Guy, Oakland, CA, United States
PA Washington Research Foundation, Seattle, WA, United States (U.S. corporation)
Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 5821055 19981013
AI US 1995-468451 19950606 (8)
RLI Continuation of Ser. No. US 1993-144095, filed on 28 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-691639, filed on 25 Apr 1991, now abandoned which is a continuation of Ser. No. US 1986-818523, filed on 13 Jan 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-692001, filed on 14 Jan 1985, now abandoned
DT Utility
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Rees, Dianne
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and **compositions** are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of **Chlamydia trachomatis**. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a .beta.-galactosidase promoter and terminator is provided.

Recombinant phage .lambda.gt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.

L5 ANSWER 70 OF 98 USPATFULL

AN 1998:108030 USPATFULL
TI Sperm as immunogen carriers
IN Scofield, Virginia L., 372 Redwood Dr., Pasadena, CA, United States 91105
PI US 5804191 19980908
AI US 1997-865724 19970530 (8)
RLI Continuation-in-part of Ser. No. US 1995-406299, filed on 17 Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-343008, filed on 21 Nov 1994, now abandoned
DT Utility
EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Sandals, William
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1179
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Vaccine compositions**, contraceptives, and gene therapy delivery vectors are disclosed in which sperm cells or components thereof are used to deliver immunogens or selected gene sequences to target cells both in vitro and in vivo. Methods of making the **vaccine compositions**, contraceptives, and gene therapy delivery formulations are disclosed. Methods of vaccination, contraception, and gene therapy are also disclosed.

L5 ANSWER 71 OF 98 USPATFULL
AN 1998:88700 USPATFULL
TI Adeno-associated virus materials and methods
IN Johnson, Philip R., Gahanna, OH, United States
PA Children's Hospital, Inc., Columbus, OH, United States (U.S. corporation)
PI US 5786211 19980728
AI US 1995-475391 19950607 (8)
RLI Division of Ser. No. US 1994-254358, filed on 6 Jun 1994, now patented, Pat. No. US 5658785
DT Utility
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Yucel, Irem
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 911
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for **treatment** of neurological disorders.

L5 ANSWER 72 OF 98 USPATFULL
AN 1998:82562 USPATFULL
TI Method and system for enhanced production of commercially important exoproteins in gram-positive bacteria
IN Kontinen, Vesa, Helsinki, Finland
Sarvas, Matti, Helsinki, Finland
PA The Finnish National Public Health Institute (KTL), Helsinki, Finland (non-U.S. corporation)
PI US 5780261 19980714
WO 9419471 19940901
AI US 1996-507391 19960708 (8)
WO 1994-FI72 19940225

19960708 PCT 371 date
19960708 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1993-24154, filed on 26 Feb 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Masood, Khalid
LREP Meyer, Esq., Virginia H.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1134
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method and expression system for enhancing secretion of hyperproduced homologous and heterologous exoproteins in gram-positive bacteria such as Bacillus sp. The method and system comprise overproduction of PrsA protein in gram-positive bacterial host capable of also overproducing at least one exoprotein of interest. Use of the method and system of the invention results in greatly enhanced secretion of the synthesized exoproteins into the growth medium. Once in the growth medium these secreted exoproteins can be recovered and purified in a straightforward manner.

L5 ANSWER 73 OF 98 USPATFULL
AN 1998:72737 USPATFULL
TI **Chlamydia** major outer membrane protein
IN Agabian, Nina, San Francisco, CA, United States
Stephens, Richard, Oakland, CA, United States
Kuo, Cho-Chou, Seattle, WA, United States
Mullenbach, Guy, Oakland, CA, United States
PA Washington Research Foundation, Seattle, WA, United States (U.S. corporation)
Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 5770714 19980623
AI US 1995-466814 19950606 (8)
RLI Division of Ser. No. US 1993-144095, filed on 28 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-691639, filed on 25 Apr 1991, now abandoned which is a continuation of Ser. No. US 1986-818523, filed on 13 Jan 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-692001, filed on 14 Jan 1985, now abandoned
DT Utility
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Rees, Dianne
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and **compositions** are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of **Chlamydia trachomatis**. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a .beta.-galactosidase promoter and terminator is provided. Recombinant phage .lambda.gt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.

L5 ANSWER 74 OF 98 USPATFULL
AN 1998:61171 USPATFULL
TI Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for **vaccines**
IN Ladd, Anna Efim, Brooklyn, NY, United States

Wang, Chang Yi, Cold Spring Harbor, NY, United States
Zamb, Timothy Joseph, Stony Brook, NY, United States
PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)
PI US 5759551 19980602
WO 9425060 19941110
AI US 1995-446692 19951226 (8)
WO 1994-US4832 19940428
19951226 PCT 371 date
19951226 PCT 102(e) date
RLI Division of Ser. No. US 1995-488351, filed on 7 Jun 1995
DT Utility
EXNAM Primary Examiner: Smith, Lynette F.
LREP Morgan & Finnegan, LLP
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 37 Drawing Figure(s); 37 Drawing Page(s)
LN.CNT 3752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. When male rats are immunized with these peptides, serum testosterone drops and androgen-dependent organs atrophy significantly. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or **treatment** of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasin domain which acts as a general immune stimulator. In another aspect this invention relates to immunogenic synthetic peptides having an invasin domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, **Chlamydia** MOMP peptides, HIV V3 peptides and Plasmodium berghei.

L5 ANSWER 75 OF 98 USPATFULL
AN 1998:24927 USPATFULL
TI Polypeptides useful in prevention of **chlamydia** infection
IN Daniels, Eddie K., Hastings, NE, United States
Woollen, Neal E., Harvard, NE, United States
PA The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. government)
PI US 5725863 19980310
AI US 1991-756346 19910906 (7)
DT Utility
EXNAM Primary Examiner: Cunningham, Thomas M.
LREP Silverstein, M. Howard; Ribando, Curtis P.; Fado, John D.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 711
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a polypeptide **vaccine** and method to immunize subjects against **Chlamydia**. In particular, this invention relates to essentially pure polypeptides of **Chlamydia** psittaci strain DD-34 ranging from about 40 to 140 kilodaltons in a pharmaceutically acceptable carrier. These **compositions** are used to immunize several species of animals against **Chlamydia**. More specifically, this invention relates to the discovery of a highly immunogenic essentially pure polypeptide of

Chlamydia psittaci strain DD-34 having a molecular weight of about 96 kilodaltons.

L5 ANSWER 76 OF 98 USPATFULL
AN 1998:19818 USPATFULL
TI Human cytomegalovirus DNA sequences
IN Spaete, Richard, Belmont, CA, United States
Cha, Tai-An, San Ramon, CA, United States
PA Aviron, Mountain View, CA, United States (U.S. corporation)
PI US 5721354 19980224
AI US 1995-414926 19950331 (8)
DT Utility
EXNAM Primary Examiner: Adams, Donald E.; Assistant Examiner: Park, Hankyel T.
LREP Cserr, Luann; Dunn, Tracy
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 53 Drawing Figure(s); 53 Drawing Page(s)
LN.CNT 2025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and **compositions** for detecting HCMV infections and in immunogenic **compositions** for preventing HCMV infections.

L5 ANSWER 77 OF 98 USPATFULL
AN 1998:14646 USPATFULL
TI Method for diagnosing a patient for **chlamydia**
IN MacDonald, Alex Bruce, Amherst, MA, United States
Stuart, Elizabeth S., Amherst, MA, United States
An, Ling Ling, La Jolla, CA, United States
Whipkey, Myron D., Portland, ME, United States
PA Animal House, Inc., Portland, ME, United States (U.S. corporation)
PI US 5716793 19980210
AI US 1995-406113 19950317 (8)
RLI Continuation-in-part of Ser. No. US 1993-34572, filed on 19 Mar 1993
DT Utility
EXNAM Primary Examiner: Spiegel, Carol A.
LREP Cook, Paul J.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of detecting **chlamydia** in a extracellular sample is provided which comprises contacting the sample with an idiotypic antibody to GLXA to form an immunocomplex and detecting the immunocomplex.

L5 ANSWER 78 OF 98 USPATFULL
AN 97:112166 USPATFULL
TI Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
IN Lees, Andrew, Silver Spring, MD, United States
PA Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)
PI US 5693326 19971202
AI US 1995-456694 19950601 (8)
DCD 20120322
RLI Continuation of Ser. No. US 1995-408717, filed on 22 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-124491, filed on 22 Sep 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapura
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

CLMN Number of Claims: 19
ECL Exemplary Claim: 1,13
DRWN 17 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1844
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a process for producing an immunogenic construct comprising activating at least one first carbohydrate-containing moiety with CDAP, and covalently joining the activated first moiety to a second moiety. Preferably, the first moiety is a polysaccharide and the second moiety is a protein. Immunogenic constructs are prepared by this process using either direct or indirect conjugation of the first and second moieties.

L5 ANSWER 79 OF 98 USPATFULL
AN 97:88734 USPATFULL
TI Selective maintenance of a recombinant gene in a population of **vaccine** cells
IN Curtiss, III, Roy, St. Louis, MO, United States
PA Washington University, St. Louis, MO, United States (U.S. corporation)
PI US 5672345 19970930
AI US 1995-402308 19950310 (8)
RLI Continuation of Ser. No. US 1992-990361, filed on 15 Dec 1992, now abandoned which is a continuation of Ser. No. US 1988-251304, filed on 3 Oct 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-106072, filed on 7 Oct 1987, now abandoned
DT Utility
EXNAM Primary Examiner: Vogel, Nancy T.
LREP Howell & Haferkamp, L.C.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 2348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention encompasses methods of maintaining desired recombinant genes in a genetic population of cells expressing the recombinant gene. The methods utilize mutant cells which are characterized by a lack of a functioning native gene encoding an enzyme which is essential for cell survival, wherein this enzyme catalyzes a step in the biosynthesis of an essential cell wall structural component and the presence of a first recombinant gene encoding an enzyme which is a functional replacement for the native enzyme, wherein the first recombinant gene cannot replace the defective chromosomal gene. The first recombinant gene is structurally linked to a second recombinant gene encoding a desired product. Loss of the first recombinant gene causes the cells to lyse when the cells are in an environment where a product due to the expression of the first recombinant gene is absent. The invention also encompasses methods of creating and isolating mutant cells with the above characteristics. The cells of the invention are useful for commercial production of desired products, for components of **vaccines** for immunizing individuals, and for release into the environment.

L5 ANSWER 80 OF 98 USPATFULL
AN 97:73593 USPATFULL
TI Acridinone derivative, **compositions** containing same and a method for using same to treat **Chlamydia trachomatis**
IN Chizhov, Novomir Pavlovich, St.-Petersburg, Russian Federation
Kupchinsky, Roald Antonovich, St.-Petersburg, Russian Federation
Alekseeva, Ljudmila Evgenievna, St.-Petersburg, Russian Federation
Kovalenko, Aleksei Leonidovich, St.-Petersburg, Russian Federation
Borisova, Margarita Alekseevna, St.-Petersburg, Russian Federation
PA Limited Liability Partnership "POLYSAN", St-Petersburg, Russian Federation (non-U.S. corporation)
PI US 5658886 19970819

WO 9422837 19941013
AI US 1994-351385 19941207 (8)
WO 1994-RU32 19940223
19941207 PCT 371 date
19941207 PCT 102(e) date
PRAI RU 1993-93017260 19930401
DT Utility
EXNAM Primary Examiner: Wilson, James O.
LREP Marshall, O'Toole, Gerstein, Murray & Borun
CLMN Number of Claims: 3
ECL Exemplary Claim: 1,3
DRWN No Drawings
LN.CNT 483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The claims cover a bioactive compound N-methyl-N-.alpha.-D-glucopyranosil-ammonium-2-acridone-9-on-10-yl-acetate designated CYCLOFERONE which was obtained by chemical synthesis and is a heterocyclic compound. Specifically CYCLOFERONE is an acridanone derivative of formula ##STR1## CYCLOFERONE exhibits interferonogenic, anti-vital (including anti-HIV), anti-parasitic, anti-promotive, and radioprotective effects.

L5 ANSWER 81 OF 98 USPATFULL
AN 97:70717 USPATFULL
TI Oral **vaccine** comprising anti-idiotypic antibody to **chlamydia** glycolipid exoantigen and process
IN MacDonald, Alex Bruce, Hatfield, MA, United States
Whittum-Hudson, Judith A., Elkton, MD, United States
Saltzman, William Mark, Baltimore, MD, United States
PA The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
University of Massachusetts, Amherst, MA, United States (U.S. corporation)
PI US 5656271 19970812
AI US 1995-466752 19950606 (8)
RLI Continuation of Ser. No. US 1994-213863, filed on 16 Mar 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-34572, filed on 19 Mar 1993
DT Utility
EXNAM Primary Examiner: Loring, Susan A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 2188
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A genus specific **chlamydia** oral or injectable **vaccine** is provided which comprises an anti-idiotype antibody capable of producing in an animal an anti-idiotypic antibody or Fab fragment thereof enclosed in microspheres formed of a pharmacologically acceptable polymer is capable of producing in an animal an anti-anti-idiotypic immune response (serum antibody, secretory antibody or T-cell responsee) which recognizes a glycolipid exoantigen (GLXA) of **chlamydia**. The oral or injectable **vaccine** is produced from an idiotypic antibody to GLXA which, in turn, is utilized to produce the anti-idiotypic antibody.

L5 ANSWER 82 OF 98 USPATFULL
AN 97:65865 USPATFULL
TI Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
IN Lees, Andrew, Silver Spring, MD, United States
PA Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)
PI US 5651971 19970729

AI US 1995-408717 19950322 (8)
RLI Continuation-in-part of Ser. No. US 1993-124491, filed on 22 Sep 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Achutamurthy, Ponnathapura
LREP Finnegan, Henderson, Farabow, Garrett & Dunner L.L.P.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1837
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a process for producing an immunogenic construct comprising activating at least one first carbohydrate-containing moiety with CDAP, and covalently joining the activated first moiety to a second moiety. Preferably, the first moiety is a polysaccharide and the second moiety is a protein. Immunogenic constructs are prepared by this process using either direct or indirect conjugation of the first and second moieties.

L5 ANSWER 83 OF 98 USPATFULL
AN 97:40647 USPATFULL
TI Detection of antibodies against **Chlamydia trachomatis** pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
IN Ratti, Giulio, Siena, Italy
PA Biocine S.p.A., Italy (non-U.S. corporation)
PI US 5629167 19970513
AI US 1994-229980 19940419 (8)
DT Utility
EXNAM Primary Examiner: Knode, Marian C.; Assistant Examiner: Duffy, Patricia A.
LREP Woodcock, Washburn, Kurtz, Mackiewicz & Norris; McClung, Barbara G.; Blackburn, Robert P.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an ELISA format.

L5 ANSWER 84 OF 98 USPATFULL
AN 97:29201 USPATFULL
TI Chimeric papillomavirus-like particles
IN Lowy, Douglas R., Bethesda, MD, United States
Schiller, John T., Silver Spring, MD, United States
Greenstone, Heather, Silver Spring, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5618536 19970408
AI US 1994-319467 19941006 (8)
RLI Continuation-in-part of Ser. No. US 1993-32869, filed on 16 Mar 1993, now patented, Pat. No. US 5437951 which is a continuation-in-part of Ser. No. US 1992-941371, filed on 3 Sep 1992
DT Utility
EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Chen, Michael C.
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1105
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a papillomavirus-like particle,

characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and **vaccines**.

L5 ANSWER 85 OF 98 USPATFULL
AN 96:120795 USPATFULL
TI Fusion proteins
IN Lipscombe, Martin J., Cambridge, United Kingdom
Charles, Ian G., Beckenham, United Kingdom
Fairweather, Neil F., Beckenham, United Kingdom
PA Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S. corporation)
PI US 5589384 19961231
AI US 1994-237716 19940502 (8)
RLI Continuation of Ser. No. US 1992-896003, filed on 11 Jun 1992, now abandoned
PRAI GB 1991-12553 19910611
DT Utility
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Bugaisky, Gabriele E.
LREP Nixon & Vanderhye P.C.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 773
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A fusion protein suitable for use as a **vaccine** comprises an amino acid sequence having biological activity which is fused via an intervening hinge comprising from two to eight glycine-proline repeats to the C-terminus of sufficient of the amino acid sequence of a B subunit of an enterotoxin which is capable of ADP-ribosylation of a GTPase.

L5 ANSWER 86 OF 98 USPATFULL
AN 96:116111 USPATFULL
TI Dual carrier immunogenic construct
IN Mond, James J., Potomac, MD, United States
Lees, Andrew, Baltimore, MD, United States
PA Henry Jackson Foundation, Rockville, MD, United States (U.S. corporation)
PI US 5585100 19961217
AI US 1995-402565 19950313 (8)
RLI Continuation of Ser. No. US 1993-126017, filed on 24 Sep 1993, now abandoned which is a continuation of Ser. No. US 1992-834067, filed on 11 Feb 1992, now abandoned
DT Utility
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Krsek-Staples, Julie
LREP Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1143
AB A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, **treatment**, and prevention of diseases.

L5 ANSWER 87 OF 98 USPATFULL
AN 95:52114 USPATFULL

TI **Vaccines** containing avirulent phop-type microorganisms
IN Curtiss, III, Roy, St. Louis, MO, United States
Galan, Jorge, St. Louis, MO, United States
PA Washington University, St. Louis, MO, United States (U.S. corporation)
PI US 5424065 19950613
AI US 1992-981935 19921119 (7)
RLI Continuation of Ser. No. US 1989-331979, filed on 31 Mar 1989
DT Utility
EXNAM Primary Examiner: Sidberry, Hazel F.
LREP Rogers, Howell & Haferkamp
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The phoP gene and its equivalents are of a type which have "global regulation of pathogenicity", i.e., they coordinately regulate a number of genes including those that encode bacterial virulence factors. In Salmonella, the phoP gene product also controls the expression of non-specific acid phosphatase from the phoN gene. A central feature of the invention are microorganisms which are avirulent as a result, in whole or in part, of a mutation in phoP, but which retain their immunogenicity. These cells are suitable as components of live **vaccines**.

L5 ANSWER 88 OF 98 USPATFULL
AN 94:104475 USPATFULL
TI Method for mycoplasma detection in a biological sample
IN Baseman, Joel B., San Antonio, TX, United States
Su, C. J., San Antonio, TX, United States
Dallo, S. F., San Antonio, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5369005 19941129
AI US 1992-965055 19921022 (7)
RLI Continuation of Ser. No. US 1990-558886, filed on 27 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1987-118967, filed on 19 Nov 1987, now patented, Pat. No. US 5026636 which is a continuation-in-part of Ser. No. US 1987-4767, filed on 9 Jan 1987, now patented, Pat. No. US 4945041
DT Utility
EXNAM Primary Examiner: Parr, Margaret; Assistant Examiner: Sisson, Bradley L.
LREP Arnold, White & Durkee
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 2114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for detecting mycoplasma in a biological sample through the application of nucleic acid hybridization techniques. More specifically, the instant invention details a method of detecting a wide variety of mycoplasma in a biological sample by employing a polynucleotide segment encoding a portion of M. pneumoniae P1 polypeptide.

L5 ANSWER 89 OF 98 USPATFULL
AN 94:28876 USPATFULL
TI Method for purifying an outer membrane protein of Haemophilus influenzae
IN Murphy, Timothy F., East Amherst, NY, United States
Apicella, Michael A., Pendleton, NY, United States
PA Research Foundation of State University of New York, Albany, NY, United States (U.S. corporation)
PI US 5300632 19940405
AI US 1991-807049 19911212 (7)

RLI Continuation-in-part of Ser. No. US 1989-330229, filed on 29 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-92948, filed on 8 Oct 1987, now patented, Pat. No. US 5173294 And a continuation-in-part of Ser. No. US 1986-932872, filed on 18 Nov 1986, now abandoned
DT Utility
EXNAM Primary Examiner: Wityshyn, Michael G.; Assistant Examiner: Sayala, C.
LREP Nixon Hargrave Devans & Doyle
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for purification of a surface exposed, immunogenic outer membrane protein of Haemophilus influenzas which is conserved amongst strains. The protein, designated P6, is relatively free of detergent, contaminating RNA and undesirable cellular components.

In accordance with the present invention, there is provided a method for purifying an immunogenic outer membrane protein of H. influenzas consisting essentially of:

a) suspending H. influenzas micro-organisms by incubating the organisms in a detergent buffer to form an insoluble fraction comprising the outer membrane protein and peptidoglycan component and a soluble fraction comprising the remainder of the cellular components;

b) separating the insoluble fraction from the soluble fraction;

c) suspending the insoluble fraction in detergent buffer containing RNase and allowing for RNA digestion;

d) separating the insoluble fraction from the soluble fraction comprising the RNase and digested RNA;

e) solubilizing the insoluble fraction by heat-treating in a detergent-free buffer; and

f) separating the soluble fraction containing the purified outer membrane protein from the insoluble fraction containing the peptidoglycan component.

L5 ANSWER 90 OF 98 USPATFULL
AN 91:49574 USPATFULL
TI Contraceptive device
IN Zelson, Steve T., 209 Mulberry La., Larchmont, NY, United States 10538
PI US 5025800 19910625
AI US 1988-148568 19880126 (7)
DT Utility
EXNAM Primary Examiner: Rosenbaum, C. Fred; Assistant Examiner: Rose, Sharon
LREP Zelson, Steve T.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 803
AB This invention relates to contraceptive devices. More particularly, this invention relates to novel contraceptive devices for males and females which provide immunological barriers to the spread of sexually transmitted diseases along with related methods to prevent the spread of these diseases.

L5 ANSWER 91 OF 98 USPATFULL
AN 89:30045 USPATFULL

TI Process for labeling single-stranded nucleic acids and hybridizaiton probes
IN Watson, Robert M., Berkeley, CA, United States
Sheldon, III, Edward L., Oakland, CA, United States
Snead, Richard M., Oakland, CA, United States
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 4822731 19890418
AI US 1986-819490 19860109 (6)
DT Utility
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Krupen, Karen
LREP Kaster, Kevin R.; Hasak, Janet E.; Halluin, Albert P.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1526
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acids may be labeled by complexing the alkylating moiety of a labeling reagent into a single-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a single-stranded hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A--[B--L

where A is an alkylating moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the alkylating and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.

L5 ANSWER 92 OF 98 USPATFULL
AN 89:9403 USPATFULL
TI Carbamic acid ester useful for preparing a nucleic acid probe
IN Levenson, Corey H., Oakland, CA, United States
Mullis, Kary B., Kensington, CA, United States
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 4803297 19890207
AI US 1987-72339 19870713 (7)
RLI Division of Ser. No. US 1986-888252, filed on 21 Jul 1986, now patented, Pat. No. US 4705886 which is a division of Ser. No. US 1985-791332, filed on 25 Oct 1985, now patented, Pat. No. US 4617261 which is a continuation-in-part of Ser. No. US 1984-683263, filed on 18 Dec 1984, now patented, Pat. No. US 4582789 which is a continuation-in-part of Ser. No. US 1984-591811, filed on 21 May 1984, now abandoned
DT Utility
EXNAM Primary Examiner: Lee, Mary C.; Assistant Examiner: Whittenbaugh, Robert C.
LREP Halluin, Albert P.; Hasak, Janet E.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic

acid. Preferably, the labeled nucleic acid is hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A--[B--L

where A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.

L5 ANSWER 93 OF 98 USPATFULL
AN 88:40765 USPATFULL
TI Precursor to nucleic acid probe
IN Levenson, Corey H., Oakland, CA, United States
Mullis, Kary B., Kensington, CA, United States
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 4754065 19880628
AI US 1987-72536 19870713 (7)
RLI Division of Ser. No. US 1986-888252, filed on 21 Jul 1986, now patented, Pat. No. US 4705886 which is a continuation-in-part of Ser. No. US 1985-791332, filed on 25 Oct 1985, now patented, Pat. No. US 4617261 which is a continuation-in-part of Ser. No. US 1984-683263, filed on 18 Dec 1984, now patented, Pat. No. US 4582789 which is a continuation-in-part of Ser. No. US 1984-591811, filed on 21 Mar 1984, now abandoned
DT Utility
EXNAM Primary Examiner: Schwartz, Richard A.
LREP Halluin, Albert P.; Hasak, Janet E.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2120
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A] [B] L

where A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.

L5 ANSWER 94 OF 98 USPATFULL
AN 88:37773 USPATFULL
TI Precursor to nucleic acid probe

IN Levenson, Corey H., Oakland, CA, United States
Mullis, Kary B., Kensington, CA, United States
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 4751313 19880614
AI US 1987-72531 19870713 (7)
RLI Division of Ser. No. US 1986-888252, filed on 21 Jul 1986, now patented, Pat. No. US 4705886 And Ser. No. US 1985-791332, filed on 25 Oct 1985, now patented, Pat. No. US 4617261 which is a continuation-in-part of Ser. No. US 1984-683263, filed on 18 Dec 1984, now patented, Pat. No. US 4582789 which is a continuation-in-part of Ser. No. US 1984-591811, filed on 21 Mar 1984, now abandoned
DT Utility
EXNAM Primary Examiner: Schwartz, Richard A.
LREP Halluin, Albert P.; Hasak, Janet E.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A][B]L

where A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moeity and L is biotin.

L5 ANSWER 95 OF 98 USPATFULL
AN 87:78077 USPATFULL
TI Precursor to nucleic acid probe
IN Levenson, Corey H., Oakland, CA, United States
Mullis, Kary B., Kensington, CA, United States
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 4705886 19871110
AI US 1986-888252 19860721 (6)
RLI Division of Ser. No. US 1985-791332, filed on 25 Oct 1985, now patented, Pat. No. US 4617261 which is a continuation-in-part of Ser. No. US 1984-683263, filed on 18 Dec 1984, now patented, Pat. No. US 4582789 which is a continuation-in-part of Ser. No. US 1984-591811, filed on 21 Mar 1984, now abandoned
DT Utility
EXNAM Primary Examiner: Schwartz, Richard A.
LREP Hasak, Janet E.; Halluin, Albert P.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 2137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the

complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A--[B--L

where A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5', 8-trimethylpsoralen moiety and L is biotin.

This patent application is a divisional application of copending U.S. Ser. No. 791,332 filed Oct. 25, 1985, now U.S. Pat. No. 4,617,261, which is a continuation-in-part application (CIP) of copending U.S. Ser. No. 683,263 filed Dec. 18, 1984, now U.S. Pat. No. 4,582,789 which is a CIP of copending U.S. Ser. No. 591,811 filed Mar. 21, 1984, now abandoned. This patent application is also related to copending U.S. application Ser. No. 791,323 filed Oct. 25, 1985.

L5 ANSWER 96 OF 98 USPATFULL
AN 86:57896 USPATFULL
TI Process for labeling nucleic acids and hybridization probes
IN Sheldon, III, Edward L., Oakland, CA, United States
Levenson, Corey H., Oakland, CA, United States
Mullis, Kary B., Kensington, CA, United States
Rapoport, Henry, Berkeley, CA, United States
Watson, Robert M., Berkeley, CA, United States
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 4617261 19861014
AI US 1985-791332 19851025 (6)
RLI Continuation-in-part of Ser. No. US 1984-683263, filed on 18 Dec 1984 which is a continuation-in-part of Ser. No. US 1984-591811, filed on 21 Mar 1984
DT Utility
EXNAM Primary Examiner: Nucker, Christine M.
LREP Halluin, Albert P.; Hasak, Janet E.
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 2330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A--[B--L

where A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moeity and L is biotin.

L5 ANSWER 97 OF 98 USPATFULL
AN 86:21811 USPATFULL
TI Process for labeling nucleic acids using psoralen derivatives
IN Sheldon, III, Edward L., Oakland, CA, United States
Levenson, Corey H., Oakland, CA, United States
Mullis, Kary B., Oakland, CA, United States
Rapoport, Henry, Berkeley, CA, United States
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 4582789 19860415
AI US 1984-683263 19841218 (6)
RLI Continuation-in-part of Ser. No. US 1984-591811, filed on 21 Mar 1984, now abandoned
DT Utility
EXNAM Primary Examiner: Nucker, Christine M.
LREP Halluin, Albert P.; Hasak, Janet E.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A labeling reagent of the formula:

[A][B]L

is prepared where A is an alkylating intercalation moiety, B is a divalent organic spacer arm moiety with a straight chain of at least two carbon atoms, and L is a monovalent label moiety capable of producing a detectable signal, e.g., a signal detectable by spectroscopic, photochemical, chemical, immunochemical or biochemical means. Preferably A is a 4'-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted 4,5',8-trimethylpsoralen moiety.

This reagent may be used to label nucleic acids, preferably DNA, by intercalating the alkylating intercalation moiety of the reagent into an at least partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hydridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive.

This reagent may also be used in chromosome banding to label specific regions of chromosomes and thereby differentiate them.

L5 ANSWER 98 OF 98 USPATFULL
AN 78:56108 USPATFULL
TI Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU)
IN Caldwell, Harlan D., Seattle, WA, United States
Kuo, Cho-Chou, Seattle, WA, United States
Kenny, George E., Seattle, WA, United States
PA Research Corporation, New York, NY, United States (U.S. corporation)
PI US 4118469 19781003
AI US 1976-680927 19760427 (5)
DT Utility
EXNAM Primary Examiner: Padgett, Benjamin R.; Assistant Examiner: Nucker, Christine M.
LREP Cooper, Dunham, Clark, Griffin & Moran
CLMN Number of Claims: 18

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1037
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Solubilized antigens of C. trachomatis strain LGV-434 upon analysis using two-dimensional immunoelectrophoresis yielded a single antigen which was found to be consistently precipitated by sera of patients with C. trachomatis infections. This antigen as antigen-antibody complex was employed as an immunogen to prepare a rabbit monospecific antiserum to this component or antigen. This monospecific antiserum demonstrated the presence of the antigen in each of the 15 strains of C. trachomatis organisms and was non-reactive with strains of C. psittaci. The C. trachomatis specific antigen was purified by immunoadsorption chromatography using monospecific antiserum as a specific ligand covalently bound to agarose gel columns and the resulting purified antigen employed to detect antibody from the sera of lymphogranuloma venereum patients using counterimmunoelectrophoresis. When the C. trachomatis specific antigen is isotopically labeled and utilized in the highly sensitive radioimmune assay antibody to the antigen should be demonstrated and a serological test based thereon should be applicable for the serological diagnosis of non-gonococcal urethritis (NGU).

=>

* * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload

NEWS EXPRESS May 23 CURRENT WINDOWS VERSION IS V6.0a,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:10:44 ON 25 MAY 2001

=> file biosis, caba, caplus, embase, lifesci, medline, scisearch, uspatful, japio
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.30 0.30

FILE 'BIOSIS' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'CABA' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 11:11:44 ON 25 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 11:11:44 ON 25 MAY 2001

FILE 'SCISEARCH' ENTERED AT 11:11:44 ON 25 MAY 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'USPATFULL' ENTERED AT 11:11:44 ON 25 MAY 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 11:11:44 ON 25 MAY 2001

```
=> s Chlamydia
L1       59198 CHLAMYDIA

=> s l1 and composition?
L2        1447 L1 AND COMPOSITION?

=> s l2 and treatment?
L3         925 L2 AND TREATMENT?

=> s l3 and Chlamydia trachomatis
L4         339 L3 AND CHLAMYDIA TRACHOMATIS

=> s l4 and vaccine?
L5          98 L4 AND VACCINE?

=> d l5 bib ab 1-98
```